Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
May, 2026
May 2026
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Jon Faldasz about Andexanet for Factor Xa Inhibitor–Associated Acute Intracerebral Hemorrhage
Jon Faldasz/LinkedIn
Dec 24, 2025, 23:03

Jon Faldasz about Andexanet for Factor Xa Inhibitor–Associated Acute Intracerebral Hemorrhage

Jon Faldasz, Senior Director of Product and Customer Experience at InsightRX, posted on LinkedIn:

“Thinking on the FDA pulling andexanet alfa, it feels like this didn’t need to be the outcome.
I mean I understand the rationale: 10% of patients experienced a thromboembolic event, 5% more than usual care, and so andexanet alfa should probably not be first line therapy for antiXa reversal. (See)

Title: Andexanet for Factor Xa Inhibitor–Associated Acute Intracerebral Hemorrhage

Authors: Stuart J. Connolly, Mukul Sharma, Alexander T. Cohen, Andrew M. Demchuk, Anna Członkowska, Arne G. Lindgren, Carlos A. Molina, Daniel Bereczki, Danilo Toni, David J. Seiffge, David Tanne, Else Charlotte Sandset, Georgios Tsivgoulis, Hanne Christensen, Jan Beyer-Westendorf, Jonathan M. Coutinho, Mark Crowther, Peter Verhamme, Pierre Amarenco, Risto O. Roine, Robert Mikulik, Robin Lemmens, Roland Veltkamp, Saskia Middeldorp, Thompson G. Robinson, Truman John Milling, Jr., Vitor Tedim-Cruz, Wilfried Lang, Anders Himmelmann, Per Ladenvall, Mikael Knutsson, Ella Ekholm, Andrew Law, Amanda Taylor, Tetyana Karyakina, Lizhen Xu, Kate Tsiplova, Sven Poli, Bernd Kallmünzer, Christoph Gumbinger, Ashkan Shoamanesh, ANNEXA-I Investigators, AstraZeneca

Jon Faldasz about Andexanet for Factor Xa Inhibitor–Associated Acute Intracerebral Hemorrhage

But what about people who refuse PCC for religious reasons? Shouldn’t this option be available for them? Why does “not as good as the best” translate to “absolutely nobody should be allowed to give or receive it?”

And also, I can’t help but think that this is another case of trying to force fit a single dose on everybody, where a drug that could be fantastic with a little more nuanced dosing is instead entirely removed from the market. Honestly this is why I left my clinical position for a career individualizing drug dosing for patients. We can do better.

AstraZeneca if you’re on board hit me up!”

Get insights from Hemostasis Today.

Alexander T. Cohen Amanda Taylor Anders Himmelmann Andexanet Alfa Andrew Law Andrew M. Demchuk Anna Członkowska ANNEXA-I Investigators antiXa Arne G. Lindgren Ashkan Shoamanesh AstraZeneca Bernd Kallmünzer Carlos A. Molina Christoph Gumbinger Daniel Bereczki Danilo Toni David J. Seiffge David Tanne Ella Ekholm Else Charlotte Sandset FDA Georgios Tsivgoulis Hanne Christensen Health Hemostasis Hemostasis Today Jan Beyer-Westendorf Jon Faldasz Jonathan M. Coutinho Jr. Kate Tsiplova Lizhen Xu Mark Crowther Medicine Mikael Knutsson Mukul Sharma PCC Per Ladenvall Peter Verhamme Pierre Amarenco Risto O. Roine Robert Mikulik Robin Lemmens Roland Veltkamp Saskia Middeldorp Stuart J. Connolly Sven Poli Tetyana Karyakina Thompson G. Robinson thrombosis Truman John Milling Vitor Tedim-Cruz Wilfried Lang
NewsFeed